Predictive factors for sunitinib treatment response in advanced renal cell carcinoma

Are we really making steps forward?

Maristella Bianconi, Luca Faloppi, Michele Del Prete, Riccardo Giampieri, Alessandro Bittoni, Antonio Lopez-Beltran, Marina Scarpelli, Liang Cheng, Mario Scartozzi, Stefano Cascinu, Rodolfo Montironi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.

Original languageEnglish
Pages (from-to)3-13
Number of pages11
JournalAnalytical and Quantitative Cytology and Histology
Volume37
Issue number1
StatePublished - 2015

Fingerprint

Renal Cell Carcinoma
Receptor Protein-Tyrosine Kinases
Therapeutics
Neoplasms
sunitinib

Keywords

  • Angiogenesis inhibitors
  • C-reactive protein
  • Cancer treatment protocols
  • Leukocytes
  • Leukopenia
  • Neutrophils
  • Renal cell carcinoma
  • Sunitinib
  • Treatment
  • Tumor markers

ASJC Scopus subject areas

  • Anatomy
  • Histology
  • Medicine(all)

Cite this

Bianconi, M., Faloppi, L., Prete, M. D., Giampieri, R., Bittoni, A., Lopez-Beltran, A., ... Montironi, R. (2015). Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: Are we really making steps forward? Analytical and Quantitative Cytology and Histology, 37(1), 3-13.

Predictive factors for sunitinib treatment response in advanced renal cell carcinoma : Are we really making steps forward? / Bianconi, Maristella; Faloppi, Luca; Prete, Michele Del; Giampieri, Riccardo; Bittoni, Alessandro; Lopez-Beltran, Antonio; Scarpelli, Marina; Cheng, Liang; Scartozzi, Mario; Cascinu, Stefano; Montironi, Rodolfo.

In: Analytical and Quantitative Cytology and Histology, Vol. 37, No. 1, 2015, p. 3-13.

Research output: Contribution to journalArticle

Bianconi, M, Faloppi, L, Prete, MD, Giampieri, R, Bittoni, A, Lopez-Beltran, A, Scarpelli, M, Cheng, L, Scartozzi, M, Cascinu, S & Montironi, R 2015, 'Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: Are we really making steps forward?', Analytical and Quantitative Cytology and Histology, vol. 37, no. 1, pp. 3-13.
Bianconi, Maristella ; Faloppi, Luca ; Prete, Michele Del ; Giampieri, Riccardo ; Bittoni, Alessandro ; Lopez-Beltran, Antonio ; Scarpelli, Marina ; Cheng, Liang ; Scartozzi, Mario ; Cascinu, Stefano ; Montironi, Rodolfo. / Predictive factors for sunitinib treatment response in advanced renal cell carcinoma : Are we really making steps forward?. In: Analytical and Quantitative Cytology and Histology. 2015 ; Vol. 37, No. 1. pp. 3-13.
@article{d184e4ae1a9144e392ca2fb8fb504f33,
title = "Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: Are we really making steps forward?",
abstract = "Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.",
keywords = "Angiogenesis inhibitors, C-reactive protein, Cancer treatment protocols, Leukocytes, Leukopenia, Neutrophils, Renal cell carcinoma, Sunitinib, Treatment, Tumor markers",
author = "Maristella Bianconi and Luca Faloppi and Prete, {Michele Del} and Riccardo Giampieri and Alessandro Bittoni and Antonio Lopez-Beltran and Marina Scarpelli and Liang Cheng and Mario Scartozzi and Stefano Cascinu and Rodolfo Montironi",
year = "2015",
language = "English",
volume = "37",
pages = "3--13",
journal = "Analytical and Quantitative Cytopathology and Histopathology",
issn = "0301-102X",
publisher = "John Rylands University Library",
number = "1",

}

TY - JOUR

T1 - Predictive factors for sunitinib treatment response in advanced renal cell carcinoma

T2 - Are we really making steps forward?

AU - Bianconi, Maristella

AU - Faloppi, Luca

AU - Prete, Michele Del

AU - Giampieri, Riccardo

AU - Bittoni, Alessandro

AU - Lopez-Beltran, Antonio

AU - Scarpelli, Marina

AU - Cheng, Liang

AU - Scartozzi, Mario

AU - Cascinu, Stefano

AU - Montironi, Rodolfo

PY - 2015

Y1 - 2015

N2 - Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.

AB - Renal cell carcinoma is an aggressive neoplasm, frequently diagnosed incidentally in an advanced stage (local or metastatic). Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, mainly directed against the angiogenic pathway. Sunitinib is largely used in first-line treatment, but response varies widely among patients. Thus, there is an urgent need to find predictive factors able to determine whether or not a patient would respond to treatment, thereby avoiding unnecessary toxicities. In this report we review the literature focusing on clinical, pathological, and molecular predictive factors currently being studied and more promising to enter clinical practice.

KW - Angiogenesis inhibitors

KW - C-reactive protein

KW - Cancer treatment protocols

KW - Leukocytes

KW - Leukopenia

KW - Neutrophils

KW - Renal cell carcinoma

KW - Sunitinib

KW - Treatment

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=84925374364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925374364&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 3

EP - 13

JO - Analytical and Quantitative Cytopathology and Histopathology

JF - Analytical and Quantitative Cytopathology and Histopathology

SN - 0301-102X

IS - 1

ER -